Welcome to our dedicated page for Merit Med Sys news (Ticker: MMSI), a resource for investors and traders seeking the latest updates and insights on Merit Med Sys stock.
News about Merit Medical Systems, Inc. (NASDAQ: MMSI) focuses on its role as a healthcare technology and medical device company engaged in the development, manufacture, and distribution of proprietary devices for interventional, diagnostic, and therapeutic procedures. Company announcements highlight activity in cardiology, radiology, oncology, critical care, and endoscopy, as well as updates on its Cardiovascular and Endoscopy segments.
Investors and healthcare professionals following MMSI news will see earnings releases, financial guidance updates, and segment performance details reported through quarterly results and Form 8-K filings. These updates often include net sales by segment, constant currency revenue figures, and non-GAAP financial measures, along with management commentary on operating performance and outlook.
Merit’s news flow also features product and clinical milestones. The company has issued releases on the WRAPSODY Cell-Impermeable Endoprosthesis (CIE), including regulatory approvals, commercialization strategies, and 24‑month efficacy results from the WAVE trial and related registries in hemodialysis patients. Additional coverage includes updates on the SCOUT Radar Localization system in breast cancer care and milestones in its global utilization.
Another key theme in MMSI news is portfolio expansion through acquisitions. Merit has announced transactions such as the asset purchase agreement to acquire the C2 CryoBalloon device and related technology for gastrointestinal disorders and has reported the closing of this acquisition in subsequent filings. These items provide insight into how the company is broadening its Endoscopy portfolio and entering or expanding in specific therapeutic markets.
Governance and leadership developments, including CEO transitions and changes in board roles, are disclosed via press releases and Form 8-K filings and form an important part of the company’s news record. For readers tracking MMSI, this news page aggregates updates on financial performance, product developments, acquisitions, regulatory milestones, and leadership changes, offering a centralized view of the company’s publicly reported activities.
Merit Medical Systems, Inc. reported strong financial performance for Q1 2024 with a revenue increase of 8.7% to $323.5 million compared to Q1 2023. The company's GAAP operating margin improved to 11.1%, GAAP EPS rose to $0.48, and non-GAAP EPS increased to $0.77. Merit reaffirmed its fiscal year 2024 guidance with expectations of continued growth and profitability.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.